Welcome to our dedicated page for Moderna news (Ticker: MRNA), a resource for investors and traders seeking the latest updates and insights on Moderna stock.
Moderna, Inc. reports developments in mRNA medicines, including commercial vaccines, investigational respiratory vaccines, oncology programs and rare-disease candidates. News commonly covers regulatory authorizations and agency interactions for products such as Spikevax, mRESVIA, mNEXSPIKE and mCOMBRIAX, as well as clinical data for seasonal influenza, pandemic influenza and cancer immunotherapy programs including intismeran autogene and mRNA-4359.
Company updates also include quarterly financial results, revenue mix, expense actions, strategic partnerships, scientific meeting presentations and intellectual-property matters tied to Moderna's infectious disease portfolio and broader mRNA technology platform.
Moderna (NASDAQ:MRNA) has been ranked the number one large employer in BioSpace's 2023 Best Places to Work report, marking its second consecutive year in this position. CEO Stéphane Bancel highlighted the company's commitment to culture, equity, and diversity, noting a workforce of over 3,800 employees with gender parity achieved in September 2022. Moderna continues to focus on employee development through initiatives like Moderna University. The recognition is based on responses from more than 2,000 life sciences professionals, showcasing the company's strong reputation in the biopharma sector.
Moderna announced in a press release dated November 14, 2022, that its bivalent booster candidates, mRNA-1273.214 and mRNA-1273.222, have shown superior neutralizing antibody responses against Omicron variants BA.4/BA.5 in a Phase 2/3 trial involving over 500 adults. Results indicated a 15.1-fold increase in geometric mean titers for mRNA-1273.222 compared to the original booster. Both vaccines demonstrated comparable safety profiles with fewer adverse events than previous doses. This builds on earlier findings published in the New England Journal of Medicine, confirming the effectiveness of these updated vaccine candidates.
Summary not available.
Moderna (NASDAQ:MRNA) will participate in a fireside chat at the Jefferies 2022 London Healthcare Conference on November 16, 2022, at 8:30 a.m. ET. Investors can access a live webcast through the Investors section of Moderna's website, with a replay available for 30 days post-event. Moderna has evolved significantly in a decade, boasting a diverse clinical portfolio of vaccines and therapeutics, including its COVID-19 vaccine. The company is recognized as a top biopharmaceutical employer by Science.
Moderna (NASDAQ:MRNA) announced that Health Canada has authorized its second bivalent COVID-19 booster vaccine, mRNA-1273.222, which targets the Omicron BA.4/BA.5 subvariants. This authorization follows the earlier approval of mRNA-1273.214 in September 2022. The 50 µg booster dose comprises mRNA for both BA.4/BA.5 and the original SARS-CoV-2 strain. The approval is based on pre-clinical data and ongoing Phase 2/3 trials. This development underscores Moderna's rapid vaccine innovation capabilities to combat emerging COVID-19 variants.
Moderna reported Q3 2022 revenues of $3.4 billion, down from $5.0 billion in Q3 2021, primarily due to declining COVID-19 vaccine sales. The company expects $18-$19 billion in revenue from advance purchase agreements for 2022, with some delivery delays pushing $2-$3 billion to 2023. GAAP net income dropped 69% to $1.0 billion, while diluted EPS fell 67% to $2.53. Moderna completed a $3 billion share repurchase plan and continues to progress in multiple vaccine developments, including RSV and flu candidates.
Moderna, Inc. (NASDAQ: MRNA) announced that its Omicron-targeting bivalent COVID-19 booster, mRNA-1273.222, received approval from Japan's Ministry of Health, Labour and Welfare. This booster is designed for adults aged 18 and older and contains mRNA-1273 and a variant-targeting component. The approval aims to provide a stronger immune response against circulating Omicron subvariants in Japan. The Phase 2/3 trial for the vaccine is ongoing, supported by Takeda Pharmaceutical Co. for distribution during Japan's national vaccination campaign.
Summary not available.
Summary not available.
Moderna (Nasdaq: MRNA) has received a positive opinion from the European Medicines Agency's CHMP recommending conditional marketing authorization for mRNA-1273.222 (Spikevax bivalent Original/Omicron BA.4-5) as a booster for individuals aged 12 and older. This follows the recent approval of the mRNA-1273.214 vaccine targeting Omicron BA.1. The bivalent vaccine mRNA-1273.222 aims to provide protection against Omicron subvariants as winter approaches. Initial data from a Phase 2/3 trial is expected later this year, enhancing Moderna's position in the COVID-19 vaccine market.